The European Commission has granted Merck and Pfizer Inc. (PFE) authorization to market a treatment for patients that suffer from metastatic Merel cell carcinoma. The monotherapy treatment, Bavencio, is offered to treat an aggressive and rare form of skin cancer. Bavencio is able to be marketed in 28 countries inContinue Reading